# Ipamorelin Research: The Selectivity Mechanism and Key Studies

> Ipamorelin research, study by study: the GHS-R1a selectivity mechanism, the human PK data, the failed Phase 2 ileus trial, rodent bone-growth findings, and the class-level cardiotoxicity signal.

Every major finding gets its own heading and its own citation. Where the data is thin, we say so.

## Before the details

If you only read one paragraph of ipamorelin research, read this one. Ipamorelin is a synthetic pentapeptide (a five-amino-acid chain) that flips on the ghrelin receptor — formally GHS-R1a — to trigger a clean pulse of growth hormone [1]. The famous part is what it *doesn't* do: it leaves cortisol and prolactin alone, which is why it's called "selective" [1]. The human evidence is small. One pharmacokinetic study mapped a roughly 2-hour half-life [2], and one Phase 2 trial for slow post-surgery bowels missed its goal and was abandoned [3]. The rest is rodent work — bone growth in rats [4], weight effects in ferrets [5] — plus review papers that all land on the same verdict: promising biology, not enough human proof [10][11]. Below, each finding gets its own section.

## What is ipamorelin peptide

The **What is ipamorelin peptide** answer in one line: it's a wholly synthetic five-amino-acid chain, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, that mimics the natural hunger hormone ghrelin at the GHS-R1a receptor to release growth hormone [1]. It was derived from the earlier peptide GHRP-1 by trimming a central dipeptide, and its non-natural amino acids make it resistant to being chewed up by enzymes [1]. It is not an endogenous human peptide — your body doesn't make it — it just borrows ghrelin's keyhole. Its molecular weight is about 712 daltons. Crucially, it is a research compound, not an approved drug [3].

## The selectivity mechanism, in detail

Ipamorelin works by activating GHS-R1a (the ghrelin receptor) on pituitary somatotrophs — the cells that store and release growth hormone [1]. Receptor activation runs through a Gq/phospholipase-C cascade, raising intracellular calcium and triggering GH release [1]. This is a different door than GHRH (growth-hormone-releasing hormone) uses, which is the entire rationale for pairing ipamorelin with a GHRH analog.

The selectivity is the headline finding. In the 1998 characterization, ipamorelin released GH potently — in conscious swine its half-maximal dose was 2.3 nmol/kg versus 3.9 nmol/kg for GHRP-6 — yet produced no significant rise in ACTH or cortisol even at doses more than 200-fold above its GH threshold [1]. That clean hormonal profile is what set it apart from every earlier growth-hormone-releasing peptide [1]. One caveat the literature is careful about: that characterization was acute, not chronic — it measured single-dose responses, not what happens over months [1].

## The human data: small, and one of it negative

Human ipamorelin evidence amounts to two studies. A 1999 population PK/PD study in eight healthy men per dose level (five 15-minute IV infusions from 4.21 to 140.45 nmol/kg) found dose-proportional kinetics, a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a single discrete GH pulse peaking around 40 minutes after dosing [2]. That is the cleanest human reading we have, and it is purely about how the drug moves through the body — not whether it helps anyone [2].

The efficacy anchor is the 2014 Phase 2 RCT (NCT00672074): 114 adults having bowel resection received 0.03 mg/kg IV twice daily for up to seven days [3]. It **missed** its primary endpoint — median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo (p=0.15) — and no ipamorelin-specific safety signal emerged in that short window (adverse events 87.5% vs 94.8% placebo) [3]. Development stopped there. That negative trial is the single most important fact in the whole record [3].

## Ipamorelin cjc-1295

The **Ipamorelin cjc-1295** pairing is the most-searched ipamorelin topic, so it's worth being precise. CJC-1295 is a GHRH analog; ipamorelin is a GHRP (ghrelin-receptor agonist). Because they stimulate GH through two complementary pathways — CJC-1295 via the GHRH/cAMP route and ipamorelin via GHS-R1a/calcium — the rationale for combining them is mechanistic synergy [1]. A 2026 orthopaedic narrative review reported that CJC-1295 combined with ipamorelin improved maximal muscle tetanic tension in a glucocorticoid-induced muscle-loss model in mice — but explicitly flagged that the evidence is limited to animals [11]. There is no human trial of the combination for any outcome; the stack rests on two single agents' separate pharmacology, not on a study of the pair [3].

## What is cjc 1295 ipamorelin

Put simply, **what is cjc 1295 ipamorelin**? It's a two-peptide pairing: a GHRH analog (CJC-1295) that keeps the GH-release "gas pedal" pressed, plus a ghrelin-receptor peptide (ipamorelin) that adds a pulse on top [1]. The idea is that two different mechanisms produce a larger, more natural-looking GH release than either alone. It is widely promoted, but it is important to keep the two molecules' evidence separate: ipamorelin's own studies do not transfer to the blend, and the blend itself has never been tested in a human trial [3]. Reviews place both inside the broader unapproved-peptide class that still needs human safety data [10].

## Does cjc-1295 ipamorelin work

The **Does cjc-1295 ipamorelin work** question has only animal-level answers. The strongest data point is the 2026 review noting improved muscle tetanic tension with the combination in a mouse glucocorticoid-muscle-loss model — and even that review stresses the evidence is confined to animal studies [11]. Ipamorelin alone reliably raises GH in the short term across species [1], and rodent work shows downstream effects like increased longitudinal bone growth [4]. But "raises GH in rats" is not the same as "produces a measured human benefit," and no controlled human outcome trial of the combination exists [3].

## Ipamorelin vs sermorelin

The **Ipamorelin vs sermorelin** distinction is a class difference. Sermorelin is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor [9]. Ipamorelin is a GHRP — it mimics ghrelin and acts on GHS-R1a [1]. They release GH through different receptors and pathways, which is precisely why some protocols pair a GHRH analog with a GHRP rather than choosing one [9][1]. A clinical review of sermorelin frames the GHRH-analog approach to restoring GH secretion in adult GH insufficiency [9]; ipamorelin has no comparable approved or reviewed clinical indication [3]. Bottom line: same goal (more GH), different mechanism, very different regulatory histories.

## Ipamorelin vs tesamorelin

The **Ipamorelin vs tesamorelin** comparison is the sharpest of the three, because tesamorelin is an *approved* GHRH analog (for one specific indication) whereas ipamorelin is not approved at all [3]. Tesamorelin, like sermorelin, works on the GHRH receptor; ipamorelin works on the ghrelin receptor [1]. The practical upshot for a reader weighing the safety record: tesamorelin carries a real human trial and labeling database behind its single indication, while ipamorelin's human record is one negative Phase 2 trial and one small PK study [2][3]. Same broad GH-secretagogue landscape, opposite ends of the evidence spectrum.

## Rodent findings and the class-level safety signal

Rodent work fills out the picture. Subcutaneous ipamorelin at 18, 90, and 450 µg/day (divided three times daily for 15 days) dose-dependently raised longitudinal bone growth in adult female rats — from 42 µm/day on vehicle to 44, 50, and 52 µm/day — with no change in total IGF-1, suggesting a partly local, GH-pulse-driven skeletal effect [4]. The most recent in-vivo study (2024) found intraperitoneal ipamorelin (1–3 mg/kg) cut cisplatin-induced body-weight loss by about 24% in ferrets, though with no anti-nausea effect [5].

The safety-relevant rodent finding sits one molecule over: a 28-day study of GSK894281, a structurally distinct GHS-R1a agonist in the same receptor class, found dose-dependent myocardial degeneration and necrosis in rats, with elevated heart-type fatty-acid-binding protein at the top doses [6]. Ipamorelin was not the tested compound, and no equivalent long-duration ipamorelin study exists — so this is a class-level cardiovascular flag, and it is the study that keeps any honest ipamorelin write-up from claiming long-term safety [6].

## What the recent reviews conclude

The 2024–2026 review literature is strikingly consistent. A 2026 review of therapeutic peptides synthesized 106 articles and concluded that while peptides are promising for metabolic, endocrine, and aesthetic conditions, more human study is needed before most new, unapproved compounds can be used safely — and it situates ipamorelin squarely in that unapproved class [10]. A 2026 structured review of injectable peptides in sports medicine classified ipamorelin as an investigational GH-axis secretagogue with an uncertain safety profile, product-quality concerns, and broad anti-doping restrictions, recommending its use be confined to rigorous research protocols [11]. Animal data also flag context-dependence: in diabetic mice, IV ipamorelin produced exaggerated GH hypersecretion (150 ± 35 µg/L vs 62 ± 11 µg/L in controls) alongside hepatic GH-receptor resistance [8], and an oral ipamorelin-derived analog (NN703) showed body-weight gain over 14 days in rats while losing some of ipamorelin's hormonal selectivity [7]. The throughline: real biology, real gaps.

---

A bright, safety-first reading of the ipamorelin record — the clean cortisol-sparing GH pulse credited as the design win it is, the lone failed human trial and the empty long-term-safety shelf kept in plain sight, and the community reports pinned to one side as anecdote; no clinic behind the page, no prescription written despite the name, and nothing here dosed, supplied, or sold.